By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Endocrine therapy is the mainstay of the management of hormone receptor (HR) positive breast cancer. Until now, fulvestrant remained the only selective
Dr. Dipesh Uprety interviewed Dr. Chadi Nabhan about his new book, Toxic Exposure. Watch the video to hear more about the book and Dr. Nabhan’s involvement in three court cases involving Monsanto’s
More
By Dr. Richa Parikh Karmanos Cancer Institute & Dr. Harsh Parmar Hackensack Meridian Health A multicenter retrospective study, which was conducted at 11 academic centers across the United States, reported a
More
SEATTLE, WA – The Binaytara Foundation, a non-profit organization dedicated to improving healthcare in underserved communities, is proud to announce the 2023 Summit on Cancer Health Disparities (SCHD), which will take place
More
By Dr. Chepsy Philip Believers Church Medical College Hospital Care of hematological cancers in India and other low- and middle-income countries (LMIC) has long had a disparity problem. An ever-increasing disease
More
By Dr. Harsh Parmar Hackensack Meridian Health In an unplanned interim analysis of an international phase-III trial (ATLAS) by Dytfeld et al., performed across 12 centers in Poland and the US,
More
On February 9th, 2023, the U.S. Food and Drug Administration approved dostarlimab-gxly for adult patients with recurrent or advanced endometrial cancer (EC) with mismatch repair deficiency (dMMR) determined by an FDA-approved test,
More
Dr. Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center shares a recent abstract from ASCO GI, IMBRAVE-151, A Phase II, randomized, double-blind placebo-controlled study of atezolizumab with or without bevacizumab in combination
More
By Dr. Abhishek A. Mangaonkar Mayo Clinic The phase 2 FIGHT-203 trial (NCT#03011372) studied 28 patients with relapsed/refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. FGFR1 rearrangement should be suspected in patients who
More
On February 3, 2023, the U.S. Food and Drug Administration approved sacituzumab govitecan-hziy for women 18 years or older with HR+/HER2-Metastatic Breast Cancer refractory to or relapsed after at least 2, and
More
Dr. Daneng Li of City of Hope Comprehensive Cancer Center shares a recent abstract from ASCO GI, NRG/RTOG 1112, a randomized phase III study of sorafenib versus stereotactic body radiation therapy followed
More